Recombinant Mouse Receptor-type tyrosine-protein phosphatase epsilon (Ptpre)

What is Receptor-type Tyrosine-protein Phosphatase Epsilon (Ptpre)?

Receptor-type tyrosine-protein phosphatase epsilon (Ptpre) is a membrane-bound protein phosphatase that belongs to the broader family of protein tyrosine phosphatases. It shares high homology with receptor type protein tyrosine phosphatase alpha (PTPRA), making it part of an important regulatory class of enzymes. In mice, the PTPRE gene is located on chromosome 7, while the human homolog is mapped to chromosome 10q26. The human version shows approximately 94% sequence homology with its murine and rat counterparts, indicating strong evolutionary conservation of this protein's function .

What are the different isoforms of Ptpre and their subcellular localization?

Ptpre exists in two main isoforms: membrane-bound Ptpre (memPTPRE) and cytoplasmic Ptpre (cytPTPRE). These isoforms result from alternative promoter usage and exhibit distinct subcellular localizations that directly influence their function. The membrane-bound isoform contains a transmembrane domain and is primarily found at the cell surface, while the cytoplasmic isoform lacks this domain and is distributed throughout the cytoplasm. The differential expression of these isoforms is tissue-specific and varies under different physiological and pathological conditions .

What primary signaling pathways does Ptpre regulate?

Ptpre primarily regulates signaling through the Src family kinases (SFKs), which are non-receptor tyrosine kinases involved in multiple cellular processes including proliferation, differentiation, and survival. Ptpre can dephosphorylate the inhibitory tyrosine residue of SFKs, thereby activating these kinases. Additionally, Ptpre regulates receptor tyrosine kinase signaling pathways, including insulin receptor signaling, PDGFR signaling, and EGFR signaling. Interestingly, the regulatory effect on these pathways appears to differ between normal and cancer cells .

How does Ptpre expression vary across different tissues?

Ptpre expression demonstrates significant tissue specificity. It is highly expressed in vascular endothelium, nerve cells, hematopoietic cells (particularly mast cells), and osteoclasts. In normal mammary glands, Ptpre expression is relatively low, but memPTPRE expression is upregulated during pregnancy and mammary gland regression. Ptpre expression also varies during development and in response to physiological stimuli, suggesting that its regulation is complex and contextually dependent .

What mechanisms regulate the expression and activity of Ptpre in normal versus cancer cells?

The regulation of Ptpre expression and activity involves multiple mechanisms that differ between normal and cancer cells. In cancer cells, particularly breast cancer, Ptpre expression can be upregulated through the EGFR and Erk1/2 pathway in response to stimuli such as PMA, FGF, and serum. This creates a positive feedback loop where EGFR, Erk, and Ptpre mutually enhance each other's activation. Notably, in normal cells, Ptpre inhibits insulin receptor and PDGFB signaling, while in cancer cells, it positively regulates EGFR signaling, indicating a context-dependent function .

MicroRNA regulation represents another important control mechanism. In etoposide-resistant retinoblastoma cells, miR631 has been found to negatively regulate Ptpre expression. When miR631 is overexpressed, Ptpre protein levels decrease significantly, resulting in reduced proliferation and increased apoptosis, mirroring the effects observed following Ptpre knockdown .

How does Ptpre contribute to chemotherapy resistance mechanisms?

Ptpre plays a significant role in chemotherapy resistance, particularly in retinoblastoma cells resistant to etoposide. Research indicates that Ptpre knockdown in etoposide-resistant retinoblastoma cell lines results in significantly increased apoptosis levels. This apoptosis is caspase-dependent, as demonstrated by the reduction in cell death following treatment with the broad-spectrum caspase inhibitor Boc-D-Fmk after Ptpre knockdown .

Furthermore, Ptpre depletion contributes to the re-sensitization of resistant cells to chemotherapeutic drugs. Treatment of Ptpre-depleted etoposide-resistant retinoblastoma cells with etoposide results in significantly decreased cell viability compared to Ptpre knockdown alone, indicating that Ptpre depletion increases the susceptibility of resistant cells to this chemotherapeutic agent .

What is the relationship between Ptpre and downstream signaling molecules in different cell types?

The relationship between Ptpre and downstream signaling molecules varies significantly between cell types. In etoposide-resistant retinoblastoma cell lines, Ptpre knockdown produces different effects on signaling molecules:

These differences highlight the cell type-specific nature of Ptpre's regulatory functions and suggest that Ptpre modulates multiple signaling pathways simultaneously but with varying effects depending on the cellular context .

How does Ptpre modulate Src family kinase activity in different physiological contexts?

Ptpre modulates Src family kinase activity through direct dephosphorylation of inhibitory phosphorylation sites. In mammary tumor cells, Ptpre regulates the phosphorylation of multiple Src family kinases, including Src, Yes, and Fyn, leading to their activation and contributing to oncogenesis. Interestingly, despite the close relationship between these kinases, research shows that expression of Src, but not Yes or Fyn, can rescue the morphological phenotype of Ptpre-deficient tumor cells, indicating functional specificity among these related kinases .

In normal cells, the interaction between Ptpre and Src can be regulated by other proteins and cellular processes. For example, integrin activation can phosphorylate Y638 of cytPTPRE, which is necessary for binding with Src and subsequent Src activation. Additionally, Neu can phosphorylate Y695 of Ptpre, which is necessary for Src activation in mammary tumor cells .

What are the optimal conditions for expressing and purifying recombinant mouse Ptpre?

For optimal expression and purification of recombinant mouse Ptpre, a Baculovirus expression system is commonly employed to maintain the protein's natural characteristics. The expression should focus on specific regions of the protein sequence depending on the intended research application. For example, some commercially available recombinant Ptpre focuses on the amino acid sequence between positions 1631 to 1907 of the natural protein, constituting a partial-length protein .

To facilitate purification and detection, the recombinant protein can be equipped with an N-terminal 10xHis-tag and a C-terminal Myc-tag. These tags allow for efficient purification using affinity chromatography techniques and easy detection in various laboratory procedures. The purified protein should achieve at least 85% purity as validated by SDS-PAGE to ensure reliable experimental results .

What experimental approaches are most effective for studying Ptpre phosphatase activity?

The most effective experimental approaches for studying Ptpre phosphatase activity include:

• In vitro phosphatase assays: Using purified recombinant Ptpre and synthetic phosphopeptide substrates to measure direct dephosphorylation activity.

• Cell-based phosphorylation assays: Transfecting cells with wild-type or catalytically inactive Ptpre and measuring the phosphorylation status of known substrates.

• Knockdown/knockout studies: Using siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate Ptpre expression and observe the effects on substrate phosphorylation.

• Phospho-specific antibodies: Employing antibodies that recognize specific phosphorylated residues on Ptpre substrates to monitor phosphorylation status.

These approaches can be complemented with site-directed mutagenesis to create catalytically inactive mutants (by mutating critical residues in the phosphatase domain) or substrate-binding mutants to dissect the functional importance of specific interactions .

How can researchers effectively design Ptpre knockdown experiments to study its function?

Effective design of Ptpre knockdown experiments requires careful consideration of several factors:

• Selection of appropriate cell models: Choose cell lines that naturally express Ptpre at detectable levels and where Ptpre function is relevant to the biological process being studied.

• Knockdown method selection:

  • siRNA for transient knockdown (3-5 days)

  • shRNA for stable knockdown

  • CRISPR-Cas9 for complete knockout

• Validation of knockdown efficiency: Use Western blotting to confirm reduction in Ptpre protein levels and quantitative RT-PCR to measure mRNA levels.

• Functional readouts: Select appropriate assays based on the cell type and expected function:

  • For cancer cells: proliferation, apoptosis, colony formation, and migration assays

  • For immune cells: degranulation and cytokine production assays

  • For neurons: electrophysiological measurements

• Rescue experiments: Reintroduce wild-type or mutant Ptpre to confirm specificity of the observed phenotypes.

This systematic approach has been successfully employed in studies of etoposide-resistant retinoblastoma cells, where Ptpre knockdown resulted in significant changes in cell viability, apoptosis, and tumor growth .

What in vivo models are available for studying Ptpre function in different physiological contexts?

Several in vivo models are available for studying Ptpre function in different physiological contexts:

• Ptpre knockout mice: These provide a system-wide elimination of Ptpre function and have been used to study its role in various tissues. For example, in newborn Ptpre knockout mice, hypomyelination of sciatic nerve axons has been observed, and in the brain cortices of these mice, enhanced tyrosine phosphorylation of various potassium channels has been detected .

• Chicken chorioallantoic membrane (CAM) assay: This model has been used to study the effects of Ptpre manipulation on tumor growth and migration. Ptpre-depleted etoposide-resistant retinoblastoma cells inoculated onto the CAM develop significantly smaller tumors than control cells, demonstrating the importance of Ptpre in tumor growth .

• Tissue-specific conditional knockout models: These allow for the elimination of Ptpre in specific tissues or at specific developmental stages, helping to dissect its tissue-specific functions.

• Transgenic overexpression models: Overexpression of Ptpre in specific tissues, such as murine mammary epithelium, has been shown to lead to mammary hyperplasia and higher tumor occurrence, providing insights into its role in oncogenesis .

How does mouse Ptpre differ structurally and functionally from human PTPRE?

How does Ptpre function compare with other receptor-type protein tyrosine phosphatases?

Ptpre belongs to a subfamily of receptor-type protein tyrosine phosphatases that includes PTPRA (receptor-type protein tyrosine phosphatase alpha), with which it shares high homology. Despite this similarity, these phosphatases exhibit distinct functions:

This comparison highlights that despite structural similarities, receptor-type protein tyrosine phosphatases have evolved distinct roles in cellular signaling networks, allowing for fine-tuned regulation of phosphorylation-dependent processes .

What are the differences in Ptpre expression and function between normal and cancer cells?

Significant differences exist in Ptpre expression and function between normal and cancer cells:

• Expression levels:

  • Normal non-transformed mammary gland: Relatively low Ptpre expression

  • Mammary tumors (c-neu and v-Ha-ras induced): High memPTPRE expression

  • Normal mammary gland during pregnancy and regression: Upregulated memPTPRE expression

• Regulation of receptor tyrosine kinase signaling:

  • Normal cells: Ptpre inhibits insulin receptor and PDGFB signaling

  • Cancer cells: Ptpre positively regulates EGFR signaling

• Signaling pathway involvement:

  • In breast cancer cell lines: Ptpre contributes to Erk1/2 and Akt activation, improving cell viability and colony formation

  • In normal cells: Different pathway regulation patterns

• Response to stimuli:

  • In breast cancer cells: PMA, FGF, and serum stimulation enhance Ptpre expression through EGFR and Erk1/2 activation

  • In normal cells: Different stimuli-response patterns

These differences suggest that Ptpre undergoes context-dependent functional shifts during oncogenesis, potentially contributing to the dysregulated signaling characteristic of cancer cells.

What are the potential therapeutic applications of targeting Ptpre in cancer?

Based on current research, targeting Ptpre in cancer presents several promising therapeutic opportunities. In etoposide-resistant retinoblastoma cells, Ptpre knockdown increases apoptosis levels and reduces tumor growth, suggesting that Ptpre inhibition could be a viable therapeutic strategy. Most importantly, Ptpre depletion contributes to the re-sensitization of resistant cells to chemotherapeutic drugs like etoposide, indicating that Ptpre inhibitors could potentially overcome chemoresistance when used in combination therapy approaches .

The development of specific Ptpre inhibitors faces challenges common to phosphatase-targeting drugs, including achieving specificity and cell permeability. Alternative approaches might include:

• siRNA or antisense oligonucleotides for targeted Ptpre knockdown

• Disruption of Ptpre interactions with key signaling partners

• Targeting Ptpre upstream regulators such as miR631, which has been shown to downregulate Ptpre expression

How can advanced techniques like CRISPR-Cas9 be applied to study Ptpre function?

CRISPR-Cas9 technology offers powerful approaches for studying Ptpre function:

• Complete knockout models: Generating Ptpre knockout cell lines or animals to study phenotypic consequences of complete Ptpre loss.

• Isoform-specific knockouts: Targeting specific isoforms (membrane vs. cytoplasmic) to dissect their distinct functions.

• Domain-specific mutations: Introducing precise mutations in functional domains (phosphatase domain, protein interaction motifs) to understand structure-function relationships.

• Endogenous tagging: Adding fluorescent or affinity tags to the endogenous Ptpre gene to study localization, trafficking, and protein interactions under physiological expression levels.

• Promoter modifications: Altering the endogenous promoter to understand transcriptional regulation.

• Combinatorial knockouts: Simultaneously targeting Ptpre and related phosphatases or substrates to study functional redundancy and pathway interactions.

These approaches would provide more precise insights than traditional knockdown methods and could reveal new aspects of Ptpre biology .